Cargando…
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) pote...
Autores principales: | Langdon, Sophie, Hughes, Adina, Taylor, Molly A., Kuczynski, Elizabeth A., Mele, Deanna A., Delpuech, Oona, Jarvis, Laura, Staniszewska, Anna, Cosulich, Sabina, Carnevalli, Larissa S., Sinclair, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136876/ https://www.ncbi.nlm.nih.gov/pubmed/30221055 http://dx.doi.org/10.1080/2162402X.2018.1458810 |
Ejemplares similares
-
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity
por: Carnevalli, Larissa S., et al.
Publicado: (2018) -
Longitudinal tracking of T cell lymphomas in mice using flow cytometry
por: Kuczynski, Elizabeth A., et al.
Publicado: (2023) -
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity
por: Wang, Shan, et al.
Publicado: (2020) -
A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability
por: Kuczynski, Elizabeth A, et al.
Publicado: (2022) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)